Isovitexin (IV)

[Edit]

Homovitexin; Saponaretin

Isovitexin (IV)
Oxidative damage and inflammation are closely associated with the pathogenesis of acute lung injury (ALI). IV treatment reduced LPS-induced pro-inflammatory cytokine secretion, iNOS and COX-2 expression and decreased the generation of ROS. Consistent findings were obtained in vivo. Additionally, IV inhibited H2O2-induced cytotoxicity and apoptosis. However, these effects were partially reversed following the use of an HO-1 inhibitor in vitro. Further studies revealed that IV significantly inhibited MAPK phosphorylation, reduced NF-κB nuclear translocation, and upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) expression in RAW 264.7 cells. IV treatment effectively increased Nrf2 and HO-1 expression in lung tissues. Therefore, IV may offer a protective role against LPS-induced ALI by inhibiting MAPK and NF-κB and activating HO-1/Nrf2 pathways.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Isovitexin (IV) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Isovitexin (IV) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Isovitexin (IV) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Isovitexin (IV) CLIA Kit Customized Service Offer
n/a ELISA Kit for Isovitexin (IV) ELISA Kit Customized Service Offer